Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | Director · Executive Chair | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,214 |
Last balance in matching sequence
After 2026-08-20 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-08-20 · Sale · Disposed 19,308 · Balance 309,662 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 2 · 2026-08-20 · Sale · Disposed 7,351 · Balance 302,311 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 3 · 2026-08-20 · Sale · Disposed 97 · Balance 302,214 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,098 | $268.01 | $294,277.51 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,236 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $267.99 to $268.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,152 | $267.21 | $307,821.54 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,334 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $266.71 to $267.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 150 | $264.72 | $39,707.51 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,486 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $264.29 to $264.93. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $263.15 | $65,787.50 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,636 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 250 | $262.00 | $65,500.00 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,886 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 254 | $261.63 | $66,453.99 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,136 F3 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $261.00 to $261.80. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 08, 2020 Filed Mar 10, 2020 23:34 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 25,453 | $0.00 | $25.45 |
DisclosureSEC source: 0001093557-20-000065 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,390 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 76,187 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 23,886 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 26,848 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 74 | $243.97 | $18,053.78 |
DisclosureSEC source: 0001093557-20-000021 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,937 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,865 | $242.95 | $696,062.06 |
DisclosureSEC source: 0001093557-20-000021 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,011 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $242.636 to $243.33. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,901 | $242.36 | $460,720.66 |
DisclosureSEC source: 0001093557-20-000021 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,876 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $241.64 to $242.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,160 | $240.97 | $279,530.88 |
DisclosureSEC source: 0001093557-20-000021 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,777 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $240.59 to $241.30. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 220 | $235.00 | $51,700.00 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 10 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,937 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,139 | $233.69 | $266,172.34 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,157 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $233.29 to $234.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,720 | $232.72 | $400,273.93 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,296 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $232.29 to $233.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 260 | $230.47 | $59,922.20 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,016 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 78 | $229.28 | $17,883.84 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,276 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,189 | $228.62 | $271,833.58 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,354 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $228.22 to $229.21. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 743 | $227.76 | $169,223.97 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,543 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $227.20 to $228.10. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 132 | $226.21 | $29,859.06 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,286 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $226.15 to $226.21. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 272 | $225.46 | $61,324.68 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,418 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $225.15 to $225.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:48 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 247 | $224.76 | $55,516.71 |
DisclosureSEC source: 0001093557-20-000011 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,690 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $224.12 to $225.05. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 01:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,128 | $222.76 | $474,024.77 |
DisclosureSEC source: 0001093557-19-000251 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,937 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $222.61 to $222.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 01:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,992 | $222.12 | $886,689.47 |
DisclosureSEC source: 0001093557-19-000251 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,065 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $221.59 to $222.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 01:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 900 | $220.95 | $198,853.02 |
DisclosureSEC source: 0001093557-19-000251 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,057 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $220.55 to $221.545. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 01:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,600 | $219.68 | $571,169.04 |
DisclosureSEC source: 0001093557-19-000251 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,957 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $219.20 to $220.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 01:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 380 | $218.28 | $82,948.00 |
DisclosureSEC source: 0001093557-19-000251 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,557 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $218.15 to $218.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 23:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,500 | $158.57 | $396,422.50 |
DisclosureSEC source: 0001093557-19-000239 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,937 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $158.10 to $158.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 23:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,470 | $157.42 | $703,646.84 |
DisclosureSEC source: 0001093557-19-000239 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,437 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $157.10 to $158.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 23:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,030 | $156.75 | $474,947.35 |
DisclosureSEC source: 0001093557-19-000239 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,907 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.10 to $157.07. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 22:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,128 | $150.31 | $470,162.80 |
DisclosureSEC source: 0001093557-19-000222 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,937 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $150.19 to $150.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 22:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,866 | $149.52 | $727,578.43 |
DisclosureSEC source: 0001093557-19-000222 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,065 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $149.10 to $150.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 22:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,006 | $148.68 | $298,259.70 |
DisclosureSEC source: 0001093557-19-000222 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,931 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $148.10 to $149.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 13,542 | $150.11 | $2,032,804.52 |
DisclosureSEC source: 0001093557-19-000192 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,937 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 780 | $145.47 | $113,464.18 |
DisclosureSEC source: 0001093557-19-000192 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,479 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.44 to $145.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 89,648 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 40,272 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,547 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,162 | $170.64 | $368,923.46 |
DisclosureSEC source: 0001093557-19-000190 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,259 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $170.39 to $171.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,502 | $169.98 | $1,105,230.77 |
DisclosureSEC source: 0001093557-19-000190 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,421 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $169.39 to $170.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,336 | $170.00 | $227,120.00 |
DisclosureSEC source: 0001093557-19-000190 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,923 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 20,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-19-000183 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,259 F6 · shares: The transaction represents a gift by the Reporting Person of 20,841 shares to a charitable donor advised fund. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,729 | $156.61 | $897,230.72 |
DisclosureSEC source: 0001093557-19-000183 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,100 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $156.26 to $156.73. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,271 | $155.74 | $509,410.17 |
DisclosureSEC source: 0001093557-19-000183 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,829 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $155.15 to $156.06. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 22:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,000 | $154.53 | $154,526.50 |
DisclosureSEC source: 0001093557-19-000183 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,100 F1 · shares: On May 15, 2019, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $154.09 to $155.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,000 | $146.43 | $732,160.00 |
DisclosureSEC source: 0001093557-19-000171 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,100 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $146.06 to $146.88. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 22:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,000 | $145.32 | $145,316.00 |
DisclosureSEC source: 0001093557-19-000171 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,100 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.01 to $145.85. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,505 | $135.32 | $203,654.34 |
DisclosureSEC source: 0001093557-19-000159 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,100 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $134.99 to $135.42. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,600 | $133.33 | $213,331.04 |
DisclosureSEC source: 0001093557-19-000159 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,605 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $133.04 to $133.95. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,195 | $132.64 | $158,503.49 |
DisclosureSEC source: 0001093557-19-000159 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,205 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $132.01 to $133.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,100 | $131.41 | $144,555.51 |
DisclosureSEC source: 0001093557-19-000159 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,400 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $130.89 to $131.73. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $128.96 | $12,896.00 |
DisclosureSEC source: 0001093557-19-000159 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,500 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $127.01 | $63,504.00 |
DisclosureSEC source: 0001093557-19-000159 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,600 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $126.92 to $127.03. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| May 13, 2019 Filed May 14, 2019 22:47 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $117.11 | $11,711.00 |
DisclosureSEC source: 0001093557-19-000123 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,100 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.